Task Force Overview
From LipidomicsWiki
(Difference between revisions)
Line 2: | Line 2: | ||
The following table shows an overview of the taskforces and their corresponding LipidomicsNet partners. | The following table shows an overview of the taskforces and their corresponding LipidomicsNet partners. | ||
- | |||
- | + | <br> | |
- | + | ||
{| class="prettytable FCK__ShowTableBorders" | {| class="prettytable FCK__ShowTableBorders" | ||
|- | |- | ||
- | ! Vertical Task Forces | + | ! Vertical Task Forces |
- | + | ! Taskforce | |
- | ! Taskforce | + | ! chair |
- | + | ! co-chair | |
- | ! chair | + | |
- | + | ||
- | ! co-chair | + | |
- | + | ||
! Partner(s) | ! Partner(s) | ||
|- | |- | ||
- | | [[Task Force I|Task Force I]] | + | | [[Task Force I|Task Force I]] |
- | + | | Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | |
- | | Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | + | | [[User:Michael Wakelam|Prof. Micheal Wakelam]] |
- | + | | [[User:Gerhard Liebisch|PhD. Gerhard Liebisch]] | |
- | | [[User:Michael Wakelam|Prof. Micheal Wakelam]] | + | |
- | + | ||
- | | [[User:Gerhard Liebisch|PhD. Gerhard Liebisch]] | + | |
- | + | ||
| [[P01 UHREG|P01]], [[P02 UU|P02]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P07 UNIGRAZ|P07]], [[P10 MPG|P10]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P15 UBO|P15]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P19 ZORA|P19]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] | | [[P01 UHREG|P01]], [[P02 UU|P02]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P07 UNIGRAZ|P07]], [[P10 MPG|P10]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P15 UBO|P15]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P19 ZORA|P19]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] | ||
|- | |- | ||
- | | [[Task Force II|Task Force II]] | + | | [[Task Force II|Task Force II]] |
- | + | | Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | |
- | | Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | + | | [[User:Christoph Thiele|Dr. Christoph Thiele]] |
- | + | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] | |
- | | [[User:Christoph Thiele|Dr. Christoph Thiele]] | + | |
- | + | ||
- | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] | + | |
- | + | ||
| [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P09 JUMC|P09]], [[P10 MPG|P10]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P23 MRC|P23]], [[P24 JKU|P24]] | | [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P09 JUMC|P09]], [[P10 MPG|P10]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P23 MRC|P23]], [[P24 JKU|P24]] | ||
|- | |- | ||
- | | [[Task Force III|Task Force III]] | + | | [[Task Force III|Task Force III]] |
- | + | | Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | |
- | | Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | + | | [[User:Stefan Muellner|Dr. Stefan Müllner]] |
- | + | | [[User:Jens Hansen|Dr. Jens Hansen]] | |
- | | [[User:Stefan Muellner|Dr. Stefan Müllner]] | + | |
- | + | ||
- | | [[User:Jens Hansen|Dr. Jens Hansen]] | + | |
- | + | ||
| [[P01 UHREG|P01]], [[P07 UNIGRAZ|P07]], [[P16 EMBL|P16]], [[P20 PROTAGEN|P20]] | | [[P01 UHREG|P01]], [[P07 UNIGRAZ|P07]], [[P16 EMBL|P16]], [[P20 PROTAGEN|P20]] | ||
|- | |- | ||
- | | [[Task Force IV|Task Force IV]] | + | | [[Task Force IV|Task Force IV]] |
- | + | | Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | |
- | | Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] |
- | + | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] | |
- | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] | + | |
- | + | ||
- | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] | + | |
- | + | ||
| [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P09 JUMC|P09]] | | [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P09 JUMC|P09]] | ||
|- | |- | ||
- | | [[Task Force V|Task Force V]] | + | | [[Task Force V|Task Force V]] |
- | + | | Mouse models | |
- | | Mouse models | + | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] |
- | + | | Van Dijk | |
- | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] | + | |
- | + | ||
- | | Van Dijk | + | |
- | + | ||
| All WP 3 Partners | | All WP 3 Partners | ||
|- | |- | ||
- | | [[Task Force VI|Task Force VI]] | + | | [[Task Force VI|Task Force VI]] |
- | + | | Clinical trials and human ethics | |
- | | Clinical trials and human ethics | + | | [[User:Daniela Gasperikova|Daniela Gasperikova]] |
- | + | | Karpe | |
- | | [[User:Daniela Gasperikova|Daniela Gasperikova]] | + | |
- | + | ||
- | | Karpe | + | |
- | + | ||
| All WP 4-6 Partners | | All WP 4-6 Partners | ||
|- | |- | ||
- | ! Horizontal Task Forces | + | ! Horizontal Task Forces |
- | + | ||
! | ! | ||
! | ! | ||
Line 86: | Line 55: | ||
! | ! | ||
|- | |- | ||
- | | [[Task Force VII|Task Force VII]] | + | | [[Task Force VII|Task Force VII]] |
- | + | | Human/Mouse translational research | |
- | | Human/Mouse translational research | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] |
- | + | | [[User:Isabell Dugail|Dr. Isabell Dugail]] | |
- | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] | + | |
- | + | ||
- | | [[User:Isabell Dugail|Dr. Isabell Dugail]] | + | |
- | + | ||
| [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P12 IEE SAS|P12]], [[P13 BABRAHAM|P13]], [[P15 UBO|P15]] | | [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P12 IEE SAS|P12]], [[P13 BABRAHAM|P13]], [[P15 UBO|P15]] | ||
|- | |- | ||
- | | [[Task Force VIII|Task Force VIII]] | + | | [[Task Force VIII|Task Force VIII]] |
- | + | | LipidomicNet-Bioinformatics | |
- | | LipidomicNet-Bioinformatics | + | | [[User:Lennart Martens|Dr. Lennart Martens]] |
- | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] | |
- | | [[User:Lennart Martens|Dr. Lennart Martens]] | + | | [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P10 MPG|P10]], [[P16 EMBL|P16]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] |
- | + | ||
- | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] | + | |
- | + | ||
- | | [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P10 MPG|P10]], [[P16 EMBL|P16]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] | + | |
- | + | ||
<br> | <br> | ||
- | |||
- | <br> | + | <br> <br> |
- | + | ||
- | + | ||
- | + | <br> | |
- | + | ||
- | + | ||
- | <br> | + | <br> |
- | + | ||
- | <br> | + | <br> |
- | + | ||
+ | <br> | ||
+ | |||
+ | <br> | ||
+ | |||
+ | <br> <br> | ||
+ | |||
+ | <br> | ||
|- | |- | ||
- | | [[Task Force IX|Task Force IX]] | + | | [[Task Force IX|Task Force IX]] |
- | + | | Dissemination, training and communication | |
- | | Dissemination, training and communication | + | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] |
- | + | | [[User:Juergen Jonas|Juergen Jonas]] | |
- | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] | + | |
- | + | ||
- | | [[User:Juergen Jonas|Juergen Jonas]] | + | |
- | + | ||
| All partners | | All partners | ||
|} | |} | ||
- | <div style="border: 1px solid red; padding: 3px; font-weight: bold; margin-right: 10px;">Together the specialized vertical and the integrative horizontal Task Forces (TFs) will generate maximal integration and efficient dissemination and training.</div> | + | <div style="border: 1px solid red; padding: 3px; font-weight: bold; margin-right: 10px;">Together the specialized vertical and the integrative horizontal Task Forces (TFs) will generate maximal integration and efficient dissemination and training.</div> |
- | + | ||
[[Category:Task_Forces]] | [[Category:Task_Forces]] |
Revision as of 12:58, 5 October 2010
Overview of LipidomicNet Task Forces
The following table shows an overview of the taskforces and their corresponding LipidomicsNet partners.
Vertical Task Forces | Taskforce | chair | co-chair | Partner(s) |
---|---|---|---|---|
Task Force I | Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | Prof. Micheal Wakelam | PhD. Gerhard Liebisch | P01, P02, P04, P06, P07, P10, P11, P13, P14, P15, P17, P18, P19, P21, P22, P25 |
Task Force II | Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | Dr. Christoph Thiele | Prof. Dr. Aldona Dembinska-Kiec | P01, P04, P09, P10, P11, P13, P14, P23, P24 |
Task Force III | Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | Dr. Stefan Müllner | Dr. Jens Hansen | P01, P07, P16, P20 |
Task Force IV | Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | Prof. Dr. Gerd Schmitz | Dr. Christian Wolfrum | P01, P06, P09 |
Task Force V | Mouse models | Dr. Christian Wolfrum | Van Dijk | All WP 3 Partners |
Task Force VI | Clinical trials and human ethics | Daniela Gasperikova | Karpe | All WP 4-6 Partners |
Horizontal Task Forces | ||||
Task Force VII | Human/Mouse translational research | Prof. Dr. Gerd Schmitz | Dr. Isabell Dugail | P01, P04, P06, P12, P13, P15 |
Task Force VIII | LipidomicNet-Bioinformatics | Dr. Lennart Martens | Prof. Dr. Gerd Schmitz | P01, P06, P10, P16, P17, P18, P21, P22, P25
|
Task Force IX | Dissemination, training and communication | Prof. Dr. Aldona Dembinska-Kiec | Juergen Jonas | All partners |
Together the specialized vertical and the integrative horizontal Task Forces (TFs) will generate maximal integration and efficient dissemination and training.